TELIX PHARMACEUTICALS LIMITED (TLX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

TLX

TLX - TELIX PHARMACEUTICALS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: December
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 6.45
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$24.78

13 Jun
2025

-0.870

OPEN

$25.71

-3.39%

HIGH

$25.74

1,700,297

LOW

$24.43

TARGET
$35.00 41.2% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
TLX: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx 15.1 29.3 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx 100.0% 94.1% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 84.7 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx15.1
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx783.2 M
Book Value Per Share xxxxxxxxxxxxxxx169.8
Net Operating Cash Flow xxxxxxxxxxxxxxx43.0 M
Net Profit Margin xxxxxxxxxxxxxxx6.37 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx13.92 %
Return on Invested Capital xxxxxxxxxxxxxxx7.72 %
Return on Assets xxxxxxxxxxxxxxx5.18 %
Return on Equity xxxxxxxxxxxxxxx13.92 %
Return on Total Capital xxxxxxxxxxxxxxx12.46 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx14.2 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx21 M
Long Term Debt xxxxxxxxxxxxxxx560 M
Total Debt xxxxxxxxxxxxxxx581 M
Goodwill - Gross xxxxxxxxxxxxxxx107 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx710 M
Price To Book Value xxxxxxxxxxxxxxx14.50

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx48.5 M
Capex % of Sales xxxxxxxxxxxxxxx6.19 %
Cost of Goods Sold xxxxxxxxxxxxxxx273 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx428 M
Research & Development xxxxxxxxxxxxxxx195 M
Investments - Total xxxxxxxxxxxxxxx56 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

UBS

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

29/04/2025

1

Buy

$34.00

37.21%

The US FDA has issued a Complete Response Letter (CRL) for Telix Pharmaceuticals’ Pixclara (CDx101), and did not approve the new drug application (NDA), observes Bell Potter.

A lack of quantitative consistency in the data sets was cited, though no safety or Chemistry, Manufacturing, and Controls (CMC) issues were identified, highlights the broker.

Management will request a hearing to review the decision, with potential next steps including re-analysis of existing data or submission of additional retrospective data, and a registration delay of up to 12 months is expected.

Bell Potter views the outcome as a setback, though a clear remediation path is available given prior extensive pre-NDA discussions. It's felt there are no implications for the upcoming Zircaix registration.

The broker retains a Buy rating and lowers the target price to $34.00 from $36.00.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of 22.50 cents.
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of 61.30 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Jarden

03/03/2025

1

Buy

$29.14

17.59%

The highlight of Telix Pharmaceuticals' FY24 result was a significant upgrade to Illuccix's revenue, Jarden notes, with the FY25 revenue guidance of $1.18-1.23bn significantly higher than expected.

The broker has upgraded its forecasts, noting revenue growth is also helped by incorporating the RLS acquisition into the numbers. FY25/26/27 forecasts are lifted by 52.2%, 34.3% and 5% respectively.

The broker highlights additional value would be unlocked from R&D projects risk-adjusted cashflows as they are approved.

Target rises to $29.14 from 22.59, Buy retained.

FORECAST
Jarden forecasts a full year FY25 EPS of 45.80 cents.
Jarden forecasts a full year FY26 EPS of 64.10 cents.
Access Extra Coverage Research History >

TLX STOCK CHART

FNArena News on TLX

1
Rudi’s View: Amcor, GQG, IPH, Data#3 & Qualitas

Jun 12 2025 - Rudi's View
2
Rudi’s View: NextDC, QBE, Superloop & Woodside

Jun 05 2025 - Rudi's View
3
Rudi’s View: The Contrarians’ View

May 29 2025 - Rudi's View
4
Rudi’s View: Rate Cut Winners & AI Beneficiaries

May 22 2025 - Rudi's View
5
Rudi’s View: 30 For ’30 & Best Buy Convictions

May 15 2025 - Rudi's View

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Rudi’s View: CSL & NextDC

May 08 2025 - Rudi's View
2
Behring Margin Outlook Still Main Game For CSL

Feb 13 2025 - Australia
3
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
4
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
5
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
6
CSL Shares Breaking Free

Jul 23 2024 - Technicals
7
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
8
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
9
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
10
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps